What are the recommended treatment options for basal cell carcinoma, including surgical and non‑surgical approaches?

Treatment of Basal Cell Carcinoma

For low-risk basal cell carcinoma, curettage and electrodesiccation or standard excision with 4-mm margins are first-line treatments, while high-risk tumors require Mohs micrographic surgery or excision with complete margin assessment to minimize recurrence and preserve tissue. 1

Risk Stratification Determines Treatment Approach

Treatment selection hinges on categorizing BCCs as low-risk versus high-risk based on tumor size, location, histologic subtype, border definition, recurrence status, and perineural invasion. 1 Any single high-risk feature places the patient in the high-risk category requiring more aggressive surgical management. 1

Surgical Treatment Options

Low-Risk BCC

Curettage and Electrodesiccation (C&E)

• Achieves 5-year cure rates of 91-97% for properly selected low-risk tumors 1
• Critical limitations: Avoid in terminal hair-bearing areas (scalp, pubic, axillary regions, beard area in men) due to risk of follicular tumor extension 1
• If subcutaneous adipose is reached during curettage, convert immediately to surgical excision because the curette cannot distinguish soft tumor from adipose tissue 1
• Results are highly operator-dependent; optimal outcomes require experienced practitioners 1

Standard Excision

• Use 4-mm clinical margins for well-circumscribed BCCs <2 cm in diameter, achieving >95% complete removal 1
• Appropriate closure methods include linear repair, skin graft, or second intention healing 1
• Avoid tissue rearrangement closures (adjacent tissue transfers) until clear margins are verified, as residual tumor "seeds" may remain 1

High-Risk BCC

Mohs Micrographic Surgery (MMS)

• MMS is the preferred surgical technique for high-risk BCC because it provides intraoperative analysis of 100% of the excision margin 1
• Achieves 5-year recurrence rates of 1.0% for primary BCC and 5.6% for recurrent BCC 1
• The only prospective randomized trial showed MMS resulted in fewer recurrences than standard excision for high-risk facial BCC after 10 years follow-up 1
• Excision with complete circumferential peripheral and deep margin assessment (CCPDMA) using frozen or permanent sections is an acceptable alternative to MMS 1

Standard Excision for High-Risk Tumors

• If used instead of MMS due to clinical circumstances, wider surgical margins than 4-mm are mandatory 1
• Expect increased recurrence rates compared to MMS 1
• Delayed repair is recommended until margins are confirmed negative 1

Non-Surgical Treatment Options

These modalities are reserved for low-risk, superficial BCC when surgery or radiation is contraindicated or impractical, with the understanding that cure rates may be lower. 1

Topical Therapies

• Imiquimod and 5-fluorouracil (5-FU) are options for low-risk superficial BCC 1
• Consider only when surgical therapy is not feasible or preferred 1

Photodynamic Therapy (PDT)

• Effective for superficial and low-risk nodular BCCs using methylaminolevulinate (MAL) or aminolevulinic acid (ALA) 1, 2
• Preferred for patients with heightened cosmetic concerns due to lower scarring risk 3

Cryosurgery

• Should be considered only under select clinical circumstances when more effective therapies are contraindicated or impractical 1
• Lacks histologic margin control 1
• Recurrence rates range from 6.3% at 1 year to 39% after 2 years 1

Radiation Therapy

• Valid alternative for patients who are not surgical candidates or decline surgery, especially elderly patients >60 years 1
• Often reserved for patients over 60 due to concerns about long-term sequelae 1
• Contraindicated in genetic conditions predisposing to skin cancer (basal cell nevus syndrome, xeroderma pigmentosum) and connective tissue diseases 1
• For tumors <2 cm: use 1-1.5 cm margins with doses such as 64 Gy in 32 fractions over 6-6.4 weeks 1
• For tumors ≥2 cm: use 1.5-2 cm margins with 66 Gy in 33 fractions over 6-6.6 weeks 1
• Adjuvant radiation therapy is recommended for extensive perineural or large-nerve involvement 1

Advanced and Unresectable BCC

Hedgehog Pathway Inhibitors

• Vismodegib and sonidegib (FDA-approved) should be offered to patients with locally advanced and metastatic BCC 1, 2
• Consider for multidisciplinary tumor board consultation when negative margins are unachievable by Mohs surgery or more extensive surgical procedures 1
• Use when residual disease is present and further surgery and radiation therapy are contraindicated 1

Immunotherapy

• Cemiplimab (anti-PD1 antibody) is second-line treatment in patients with disease progression, contraindication, or intolerance to hedgehog inhibitor therapy 2

Management of Positive Margins

• If positive margins after MMS or standard excision: re-excision is preferred 1
• If further surgery is not feasible: consider radiation therapy 1
• If both surgery and radiation are contraindicated: multidisciplinary tumor board consultation to consider hedgehog pathway inhibitors or clinical trial 1

Critical Pitfalls to Avoid

• Never use C&E in hair-bearing areas due to follicular tumor extension risk 1
• Never perform complex tissue rearrangement closures before confirming negative margins 1
• Do not use cryosurgery or topical therapies for high-risk tumors due to lack of margin control and higher recurrence rates 1
• Avoid radiation therapy in patients with genetic predisposition syndromes (Gorlin syndrome, xeroderma pigmentosum) 1
• If subcutaneous fat is reached during C&E, immediately convert to excision 1

1, 2